Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GALT $11.61 1.3300 +12.94%
PVCT $2.32 0.2100 +9.95%
SRNE $10.55 0.9000 +9.33%
AMBI $6.94 0.5300 +8.27%
CYTR $3.23 0.2300 +7.67%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

INO $2.52 -0.1500 -5.62%
THLD $3.83 -0.1900 -4.73%
INFI $10.15 -0.4500 -4.25%
NYMX $5.04 -0.2199 -4.18%
KPTI $31.09 -1.3100 -4.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Investigational Anticancer Drug May Benefit Subgroup of Patients With Head and Neck Cancer

(AACR) Apr 7, 2014 - Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), the most common form of head and neck cancer, may benefit from treatment with the investigational drug dacomitinib.
read press release 



Pfizer Breast Cancer Drug Helps Revive Discarded Strategy

(Bloomberg) Apr 7, 2014 - Pfizer Inc., Eli Lilly & Co. and Novartis AG have dug an idea out of the pharmaceutical dustbin to create new medicines that are showing blockbuster potential against hard-to-treat forms of breast cancer.
read article 



GSK Investigates Bribery Claims in Iraq

(The Telegraph [UK]) Apr 7, 2014 - GlaxoSmithKline is investigating allegations of corruption against the company's Iraqi arm, just nine months after becoming embroiled in a major bribery scandal in China.
read article 



FDA Grants Breakthrough Therapy Designation To Novartis' Meningitis B Vaccine

(Forbes) Apr 7, 2014 - Novartis AG in Basel announced early this morning that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation – a rapid development track – for potential approval of Bexsero®, their innovative vaccine against type B meningococcal meningitis.
read article 



MannKind Updates Status of New Drug Application for AFREZZA(R)

(Mannkind) Apr 7, 2014 - MannKind Corporation today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA® by three months to July 15, 2014.
read corporate press release 



Boehringer Ingelheim's Oral Anticoagulant Gains New Indication

(Forbes) Apr 7, 2014 - The new oral anticoagulants continue to gain additional indications from the FDA. Earlier today Boehringer Ingelheim announced that the FDA had approved Pradaxa (dabigatran) for the treatment of venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).
read article 



Teva Asks U.S. Supreme Court to Stay Ruling in Copaxone Case

(CNBC/Reuters) Apr 7, 2014 - Teva Pharmaceutical Industries Ltd asked the U.S. Supreme Court on Monday to stop a lower court ruling from going into effect while the justices consider an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.
read article 



Sun Pharmaceutical to Buy Ranbaxy in $3.2 Billion Deal

(Wall Street Journal) Apr 7, 2014 - India's Sun Pharmaceutical is taking over domestic rival Ranbaxy Laboratories from its Japanese owner, Daiichi Sankyo, which struggled for years to turn around the company, in a deal valued at $3.2 billion.
read article (paid subscription required) 



Irish Firm to Buy Fast-growing MS-drug Maker Questcor for $5.6 Billion

(Los Angeles Times) Apr 7, 2014 - Irish pharmaceutical company.
read article (free registration required) 



Dr. Douglas Hanahan Recognized With AACR Lifetime Achievement in Cancer Research Award

(AACR) Apr 5, 2014 - Douglas Hanahan, Ph.D., director of the Swiss Institute for Experimental Cancer Research (ISREC) at the Swiss Federal Institute of Technology (EPFL), in Lausanne, Switzerland, will be honored at the AACR Annual Meeting 2014.
read press release 



Roswell Park to Present Findings on Jasco Pharmaceuticals’ Novel PIM Inhibitor at AACR 2014

(RPCI) Apr 4, 2014 - Latest studies strengthen evidence on JP11646 as effective treatment for pancreatic, bladder and blood cancers.
read press release 



More than 30 Roswell Park Research Teams to Share Findings at AACR 2014

(RPCI) Apr 4, 2014 - Highlights include studies on personalized medicine, vitamin D, diet and breast cancer, BMT outcomes.
read press release 



Two Ludwig Researchers to Give Plenary Presentations on Immunotherapy at 2014 AACR Annual Meeting

(Ludwig Institute) Apr 6, 2014 - Ludwig researchers Irving Weissman and Jedd Wolchok will each give a talk during today’s plenary session of the AACR Annual Meeting 2014, starting at 8:45 am PT.
read press release 



Chemo Can Make Food Taste Like Metal. Here's Help

(NPR/Shots blog) Apr 7, 2014 - Cancer patients often lose their appetite because chemotherapy can cause nausea. But it does something else to make food unappetizing – it changes the way things taste.
read article 



Bezos Family Donates $20 Million to Fred Hutch to Develop Therapies That ‘Melt’ Cancer

(Fred Hutchinson) Apr 7, 2014 - Largest-ever gift to the Hutch promises to save lives by broadening the application of immunotherapy to lung, ovarian, pancreatic and colon cancers.
read press release 



Genentech and PatientsLikeMe Enter Patient-Centric Research Collaboration

(PatientsLikeMe.com) Apr 7, 2014 - Companies sign multi-year services and data subscription agreement with initial focus on oncology.
read article 



Cancer Patients Access $40 Million in Financial Assistance for Lifesaving Medications Through OncologyRx Care Advantage™

(4-traders) Apr 7, 2014 - OncologyRx Care Advantage, LP, McKesson Specialty Health’s oral oncology products specialty pharmacy, announced today that they have assisted under-insured patients in obtaining $40 million in financial assistance by helping them access financial assistance programs.
read article 



NW Bio Again Sets Feuerstein Record Straight

(Yahoo! Finance) Apr 7, 2014 - Northwest Biotherapeutics today again set the record straight: Adam Feuerstein's latest, sensationalized headline claims about the Company's annual report and Phase III trial are once again factually wrong and materially misleading.
read article 



Cancer Patients Access $40 Million in Financial Assistance for Lifesaving Medications Through OncologyRx Care Advantage™

(4-traders) Apr 7, 2014 - OncologyRx Care Advantage, LP, McKesson Specialty Health’s oral oncology products specialty pharmacy, announced today that they have assisted under-insured patients in obtaining $40 million in financial assistance by helping them access financial assistance programs.
read article 



Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

(SYS-CON.com) Apr 7, 2014 - Soligenix has been awarded a Small Business Innovation Research (SBIR) grant to support the conduct of its Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
read article 



OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence

(MarketWatch) Apr 7, 2014 - OncoSec Medical Inc. will re-launch its Phase II cutaneous T-cell lymphoma (CTCL) trial under a protocol amendment.
read article 



Mersana, Takeda Team Up to Develop ADCs

(Genetic Engineering News) Apr 7, 2014 - Mersana Therapeutics inked an agreement with Millennium Pharmaceuticals, a wholly-owned subsidiary of Takeda Pharmaceutical, to develop next-generation Fleximer® antibody-drug conjugates (ADCs).
read article (free registration required) 



Roche to Pay $450 Million for IQuum

(Wall Street Journal) Apr 7, 2014 - Roche said that it has acquired privately held IQuum to strengthen its molecular diagnostics business.
read article (paid subscription required) 



Brachytherapy Helps Maintain Erectile Function in Prostate Cancer Patients Without Compromising Treatment Outcomes

(ESTRO) Apr 5, 2014 - The use of permanent brachytherapy, a procedure where radioactive sources are placed inside the prostate, into or near to the tumour, preserves erectile function in approximately 50% of patients with prostate cancer, a researcher will tell the ESTRO 33 congress today (Saturday).
read press release 



Genomic Signature Predicts Prostate Cancer Metastasis Risk

(Medscape Medical News) Apr 7, 2014 - A DNA signature obtained from biopsies from untreated prostate cancer patients can differentiate between patients at low or high risk for metastasis even when clinical predictive factors appear equal, according to new research presented here at the European Society for Radiotherapy and Oncology (ESTRO) 33 annual conference.
read article (free registration required)